ArticleEuropean journal of medicinal chemistry2017

Design of a doxorubicin-peptidomimetic conjugate that targets HER2-positive cancer cells.

Sandeep Pallerla et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.